The latest in the international biological sciences found that a single dose of cannabis extract, cannabinol (CBD), can help reduce brain dysfunction in mentally ill patients and repair the brain. A new certificate from King's College London is published in the JAMA Journal of Psychiatry.
The results of a study published in the Jama Psychiatry journal indicate that cannabisdiol (CBD) can help the brain of a mentally ill person "normalize." CBD is a harmless, non-psychoactive compound found in cannabis that has long been considered to have potent efficacy, and recently a purified CBD drug was approved by the FDA in the United States for the treatment of rare childhood epilepsy.The team studied 33 young people who have not been diagnosed with mental illness, but their symptoms are similar and painful.
Sixteen participants took a single dose of CBD and 17 participants took a placebo.
Magnetic resonance imaging (MRI) brain scans showed that among the participants taking the cannabis extract CBD, three key brain regions: the striatum, the medial temporal cortex and the midbrain, had reduced abnormal activity. This suggests that the CBD can help patients with a mental risk to re-adjust their brain activity to normal levels. The head of the study, Dr. Sagnik Bhattacharyya of King's College London, said that the main drug currently used to treat people with mental illness is the drug first discovered in the 1950s and is not suitable for everyone. Our findings have begun to unravel the brain mechanism of a new drug that is completely different from traditional antipsychotics.
Dr. Bhattacharyya emphasized that one of the main advantages of cannabidiol is that it is safe and appears to be well tolerated, making it an ideal treatment in some respects.The King's College London team is launching the first large multi-center trial to study whether cannabinol can be used to treat young people at high risk for mental illness. The trial has received a £1.85 million grant from the NHS National Institutes of Health (NIHR) and the Medical Research Council (MRC). If successful, this trial will provide clear evidence of the role of the CBD as an antipsychotic and paves the way for clinical use.
Contact us by E-mail: firstname.lastname@example.org